Dissemination Archiv

• Scientific Publications
• Scientific Presentations

Scientific Publications

Hepatocyte growth factor gene therapy enhances infiltration of macrophages and may induce kidney repair in db/db mice as a model of diabetes.
Flaquer M, Franquesa M, Vidal A, Bolaños N, Torras J, Lloberas N, Herrero-Fresneda I, Grinyó JM, Cruzado JM.
Diabetologia. 2012 Mar 30. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/22460762

Sirolimus enhances cyclosporine a-induced cytotoxicity in human renal glomerular mesangial cells.
O'Connell S, Slattery C, Ryan MP, McMorrow T.
J Transplant. 2012 2012:980910. Epub 2012 Jan 23
http://www.ncbi.nlm.nih.gov/pubmed/22315658

Mechanisms of Calcineurin Inhibitor Nephrotoxicity in Chronic Allograft Injury
C. Slattery, H. Cassidy, O. Johnston, M.P. Ryan and T. McMorrow.
in 'Chronic Kidney Disease and Renal Transplantation', 2012:1-22 M. Sahay (Ed), InTech Publications.
http://www.intechopen.com/articles/show/title/mechanisms-of-calcineurin-inhibitor-nephrotoxicity-in-chronic-allograft-injury

RhoA and Rho kinase mediate cyclosporine A and sirolimus-induced barrier tightening in renal proximal tubular cells.
Martin-Martin N, Dan Q, Amoozadeh Y, Waheed F, McMorrow T, Ryan MP, Szászi K.
Int J Biochem Cell Biol. 2012 44(1):178-88
http://www.ncbi.nlm.nih.gov/pubmed/22062948

Cyclosporine A-induced oxidative stress in human renal mesangial cells: a role for ERK 1/2 MAPK signalling.
O'Connell S, Tuite N, Slattery C, Ryan MP, McMorrow T.
Toxicol Sci. 2011 Dec 6
http://www.ncbi.nlm.nih.gov/pubmed/22147139

In-silico human genomics with GeneCards.
Stelzer G, Dalah I, Stein TI, Satanower Y, Rosen N, Nativ N, Oz-Levi D, Olender T, Belinky F, Bahir I, Krug H, Perco P, Mayer B, Kolker E, Safran M, Lancet D.
Hum Genomics. 2011 5(6):709-17
http://www.ncbi.nlm.nih.gov/pubmed/22155609

TGF-β1 mediates sirolimus and cyclosporine A-induced alteration of barrier function in renal epithelial cells via a noncanonical ERK1/2 signaling pathway.
Martin-Martin N, Slattery C, McMorrow T, Ryan MP.
Am J Physiol Renal Physiol. 2011 301(6):F1281-92
http://www.ncbi.nlm.nih.gov/pubmed/21880834

Relationship between Magnesium and Clinical Biomarkers on Inhibition of Vascular Calcification.
Salem S, Bruck H, Bahlmann FH, Peter M, Passlick-Deetjen J, Kretschmer A, Steppan S, Volsek M, Kribben A, Nierhaus M, Jankowski V, Zidek W, Jankowski J.
Am J Nephrol. 2011 35(1):31-39
http://www.ncbi.nlm.nih.gov/pubmed/22179063

Tissue inhibitor of metalloproteinases (TIMP-1), genetic markers of insulin resistance and cardiomyopathy in patients with kidney failure.
Spoto B, Testa A, Parlongo RM, Tripepi G, D'Arrigo G, Mallamaci F, Zoccali C.
Nephrol Dial Transplant. 2011 Dec 23. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/22199358

Uridine adenosine tetraphosphate activation of the purinergic receptor P2Y enhances in vitro vascular calcification.
Schuchardt M, Tölle M, Prüfer J, Prüfer N, Huang T, Jankowski V, Jankowski J, Zidek W, van der Giet M.
Kidney Int. 2011 Sep 28. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21956191

Phosphate May Promote CKD Progression and Attenuate Renoprotective Effect of ACE Inhibition.
Zoccali C, Ruggenenti P, Perna A, Leonardis D, Tripepi R, Tripepi G, Mallamaci F, Remuzzi G; for the REIN Study Group.
J Am Soc Nephrol. 2011 22(10):1923-1930
http://www.ncbi.nlm.nih.gov/pubmed/21852581

Validity of biomarkers predicting onset or progression of nephropathy in patients with Type 2 diabetes: a systematic review.
Hellemons ME, Kerschbaum J, Bakker SJ, Neuwirt H, Mayer B, Mayer G, de Zeeuw D, Lambers Heerspink HJ, Rudnicki M.
Diabet Med. 2011 Sep 13. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21913962

Survival Analysis II: Cox Regression.
Stel VS, Dekker FW, Tripepi G, Zoccali C, Jager KJ.
Nephron Clin Pract. 2011 119(3):c255-c260
http://www.ncbi.nlm.nih.gov/pubmed/21921637

Cross Talk Between the Renin-Angiotensin-Aldosterone System and Vitamin D-FGF-23-klotho in Chronic Kidney Disease.
de Borst MH, Vervloet MG, Ter Wee PM, Navis G.
J Am Soc Nephrol. 2011 Aug 18. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21852584

Oncostatin M is a novel inhibitor of TGF-{beta}1-induced matricellular protein expression.
Sarkozi R, Hauser C, Noppert SJ, Kronbichler A, Pirklbauer M, Haller VM, Grillari J, Grillari-Voglauer R, Mayer G, Schramek H.
Am J Physiol Renal Physiol. 2011 Aug 3. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21816755

Identification of beta2-microglobulin as a urinary biomarker for chronic allograft nephropathy using proteomic methods.
Johnston O, Cassidy H, O’Connell S, O’Riordan A, Gallagher W, Maguire PB, Wynne K, Cagney G, Ryan MP, Conlon PJ, McMorrow T.
Proteomics Clin Appl. 2011 5(7-8):422-31
http://www.ncbi.nlm.nih.gov/pubmed/21751411

Survival Analysis I: The Kaplan-Meier Method.
Stel VS, Dekker FW, Tripepi G, Zoccali C, Jager KJ.
Nephron Clin Pract. 2011 119(1):c83-c88.
http://www.ncbi.nlm.nih.gov/pubmed/21677442

ACE Inhibition Is Renoprotective among Obese Patients with Proteinuria.
Mallamaci F, Ruggenenti P, Perna A, Leonardis D, Tripepi R, Tripepi G, Remuzzi G, Zoccali C; for the REIN Study Group
J Am Soc Nephrol 2011 22(6):1122-1128
http://www.ncbi.nlm.nih.gov/pubmed/21527660

Insulin resistance and left ventricular hypertrophy in end-stage renal disease: association between the ENPP1 gene and left ventricular concentric remodelling.
Spoto B, Testa A, Parlongo RM, Tripepi G, Trischitta V, Mallamaci F, Zoccali C.
Nephrol Dial Transplant 2011 May 19 [Epub ahead of print].
http://www.ncbi.nlm.nih.gov/pubmed/21602183

Angioprotectin: an angiotensin II-like peptide causing vasodilatory effects.
Jankowski V, Tölle M, Santos RA, Günthner T, Krause E, Beyermann M, Welker P, Bader M, Pinheiro SV, Sampaio WO, Lautner R, Kretschmer A, van der Giet M, Zidek W, Jankowski J.
FASEB J 2011 May 31
http://www.ncbi.nlm.nih.gov/pubmed/21628446

Mapping of molecular pathways, biomarkers and drug targets for diabetic nephropathy.
Fechete R, Heinzel A, Perco P, Mönks K, Söllner J, Stelzer G, Eder S, Lancet D, Oberbauer R, Mayer G, Mayer B.
Proteomics Clin Appl 2011 Mar 11 [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21491608

Urine proteomics in kidney and urogenital diseases: Moving towards clinical applications.
Zürbig P, Dihazi H, Metzger J, Thongboonkerd V, Vlahou A
Proteomics Clin Appl 2011 Mar 31 [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21591267

Human urinary peptide database for multiple disease biomarker discovery.
Siwy J, Mullen W, Golovko I, Franke J, Zürbig P
Proteomics Clin Appl 2011 Mar 31 [Epub ahead of print]
http://onlinelibrary.wiley.com/doi/10.1002/prca.201000155/abstract

Diagnosis of subclinical and clinical acute T-cell mediated rejection in renal transplant patients by urinary proteome analysis.
Metzger J, Chatzikyrkou C, Broecker V, Schiffer E, Jänsch L, Iphöfer A, Mengel M, Mullen W, Mischak H, Haller H, Gwinner W
Proteomics Clin Appl 2011 Mar 31 [Epub ahead of print]
http://onlinelibrary.wiley.com/doi/10.1002/prca.201000153/abstract

An overview of the objectives of and the approaches to propensity score analyses.
Heinze G, Jüni P.
Eur Heart J. 2011 Feb 28. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21362706

How to Deal with Continuous and Dichotomic Outcomes in Epidemiological Research: Linear and Logistic Regression Analyses.
Tripepi G, Jager KJ, Stel VS, Dekker FW, Zoccali C.
Nephron Clin Pract 2011 118(4):c399-c406.
http://www.ncbi.nlm.nih.gov/pubmed/21346375

Vitamin D deficiency in cardiovascular and renal disease: new light shed on an old enemy.
de Borst MH.
Curr Drug Targets. 2011 12(1):1-3.
http://www.ncbi.nlm.nih.gov/pubmed/20795942

Vitamin D in chronic kidney disease: new potential for intervention.
Mirković K, van den Born J, Navis G, de Borst MH.
Curr Drug Targets. 2011 12(1):42-53.
http://www.ncbi.nlm.nih.gov/pubmed/20795938

Vitamin D deficiency: universal risk factor for multifactorial diseases?
de Borst MH, de Boer RA, Stolk RP, Slaets JP, Wolffenbuttel BH, Navis G.
Curr Drug Targets. 2011 12(1):97-106.
http://www.ncbi.nlm.nih.gov/pubmed/20795934

Identification of novel indicators of cyclosporine A nephrotoxicity in a CD-1 mouse model.
O'Connell S, Slattery C, Ryan MP, McMorrow T.
Toxicol Appl Pharmacol. 2011 Feb 23. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21354196

Sample Size Calculations.
Noordzij M, Dekker FW, Zoccali C, Jager KJ.
Nephron Clin Pract 2011 118(4):c319-c323.
http://www.ncbi.nlm.nih.gov/pubmed/21293154

Capillary rarefaction, hypoxia, VEGF and angiogenesis in chronic renal disease.
Mayer G.
Nephrol Dial Transplant. 2011 Feb 17. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21330358

Addressing the Challenge of Defining Valid Proteomic Biomarkers and Classifiers.
Dakna M, Keith H, Kalousis A, Carpentier S, Kolch W, Schanstra JP, Haubitz M, Vlahou A, Mischak H, Girolami M.
BMC Bioinformatics. 2010 11(1):594.
http://www.biomedcentral.com/1471-2105/11/594

Cost-effectiveness analysis of renal replacement therapy in Austria.
Haller M, Gutjahr G, Kramar R, Harnoncourt F, Oberbauer R
Nephrol Dial Transplant 2011 [in press]

Contrasting incremental value of estimated glomerular filtration rate and albuminuria as independent and additive predictors of cardiovascular versus renal outcomes in 27,000 high risk people.
Clase CM, Gao P, Tobe SW, McQueen MJ, Grosshennig A, Teo KK, Yusuf S, Mann JFE on behalf of the ONTARGET and TRANSCEND investigators
Ann Int Med 2011 [in press]

Cardiovascular and renal outcomes with telmisartan, ramipril or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies.
Tobe SW, Clase CM, Gao P, McQueen MJ, Grosshennig A, Wang X, Teo KK, Yusuf S, Mann JFE on behalf of the ONTARGET and TRANSCEND investigators
Circulation 2011 [in press]

Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease.
Good DM, Zürbig P, Argilés A, Bauer HW, Behrens G, Coon JJ, Dakna M, Decramer S, Delles C, Dominiczak AF, Ehrich JH, Eitner F, Fliser D, Frommberger M, Ganser A, Girolami MA, Golovko I, Gwinner W, Haubitz M, Herget-Rosenthal S, Jankowski J, Jahn H, Jerums G, Julian BA, Kellmann M, Kliem V, Kolch W, Krolewski AS, Luppi M, Massy Z, Melter M, Neusüss C, Novak J, Peter K, Rossing K, Rupprecht H, Schanstra JP, Schiffer E, Stolzenburg JU, Tarnow L, Theodorescu D, Thongboonkerd V, Vanholder R, Weissinger EM, Mischak H, Schmitt-Kopplin P
Mol Cell Proteomics. 2010 9(11):2424-37
http://www.ncbi.nlm.nih.gov/pubmed/20616184

CE-MS in biomarker discovery, validation, and clinical application.
Mischak H and Schanstra JP
Protomics Clin Appl 2010 4:1-15
http://onlinelibrary.wiley.com/doi/10.1002/prca.201000058/abstract

Vitamin D as an accelerator of atherosclerotic calcification: a D-tail that may be a Trojan horse.
Hellemons ME, Bakker SJ
Diabetologia. 2010 53(12):2688
http://www.ncbi.nlm.nih.gov/pubmed/20890744

The issue of studying the effect of interventions in renal replacement therapy -- to what extent may we be deceived by selection and competing risk?

Jager KJ, Stel VS, Zoccali C, Wanner C, Dekker FW.
Nephrol Dial Transplant. 2010 25(12):3836-9
http://www.ncbi.nlm.nih.gov/pubmed/20833688

Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria.
Andersen S, Mischak H, Zurbig P, Parving HH, Rossing P.
BMC Nephrol. 2010 Nov 1;11(1):29. [Epub ahead of print]
http://www.biomedcentral.com/1471-2369/11/29

Urinary Proteomics Based on Capillary Electrophoresis-Coupled Mass Spectrometry in Kidney Disease: Discovery and Validation of Biomarkers, and Clinical Application
Harald Mischak, Christian Delles, Julie Klein, Joost P. Schanstra
Adv Chron Kid Dis Vol 17, 6, 493-506 (November 2010)
http://www.ackdjournal.org/article/S1548-5595(10)00143-6/abstract

Adaptive trimmed t-statistics for identifying predominantly high expression in a microarray experiment.
Gleiss A, Sanchez-Cabo F, Perco P, Tong D, Heinze G.
Stat Med. 2010 Oct 20. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20963766

Multicentric Validation of Proteomic Biomarkers in Urine Specific for Diabetic Nephropathy
Alaa Alkhalaf, Petra Zürbig, Stephan J. L. Bakker, Henk J. G. Bilo, Marie Cerna, Christine
Fischer , Sebastian Fuchs , Bart Janssen, Karel Medek, Harald Mischa, Johannes M. Roob, Kasper Rossing, Peter Rossing, Ivan Rychlı´k, Harald Sourij, Beate Tiran, Brigitte M. Winklhofer-Roob, Gerjan J. Navis, for the PREDICTIONS Group
PLoS One. 2010 Oct 20;5(10):e13421.
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0013421

Urinary Collagen Fragments Are Significantly Altered in Diabetes: A Link to Pathophysiology
Maahs DM, Siwy J, Argilés À, Cerna M, Delles C, Dominiczak A., Gayrard N., Iphöfer A.,Jänsch L.,Jerums G.,Medek K.,Mischak H., et al. 2010
PLoS ONE 5(9): e13051. doi:10.1371/journal.pone.0013051
http://www.plosone.org/

GeneCards Version 3: the human gene integrator.
Safran M, Dalah I, Alexander J, Rosen N, Iny Stein T, Shmoish M, Nativ N, Bahir I, Doniger T, Krug H, Sirota-Madi A, Olender T, Golan Y, Stelzer G, Harel A, Lancet D.
Database (Oxford). 2010 Aug 5;2010:baq020. Print 2010.
http://database.oxfordjournals.org/

The Importance of Quality Control During qPCR Data Analysis
Barbara D’haene, and Jan Hellemans
Biogazelle & Ghent University
International Drug Discovery, 2010
http://www.internationaldrugdiscovery.com/

Recommendations for Biomarker Identification and Qualification in Clinical Proteomics
Harald Mischak, et al.
Sci Transl Med 25 August 2010:Vol. 2, Issue 46, p. 46ps42
http://stm.sciencemag.org/

Oncostatin M inhibits basal and TGF-ß1-induced expression of matricellular proteins in human kidney-2 cells.
Sarközi R., Hauser C., Noppert S.-J., Rudnicki M., Kronbichler A., Pirklbauer M., Mayer G.,
Schramek H.
J. Am. Soc. Nephrol. 21: 2010, in press.

EU Projekt SysKid – Systems Biology towards Novel Chronic Kidney Disease Diagnosis and Treatment
Alexander Kainz, Gert Mayer, Rainer Oberbauer, Bernd Mayer
NEPHRO-NEWS - 3/10

Proteomic biomarkers in diabetic nephropathy—reality or future promise?
Harald Mischak and Peter Rossing
Nephrol Dial Transplant. 2010 Sep;25(9):2843-5.
http://ndt.oxfordjournals.org/

SysKID
Vianda Stel
ERA-EDTA Registry Newsletter 16, June 2010
http://www.era-edta.org/

Omics Data management and Annotation
A. Harel, I. Dalah, S. Pietrovski, M. Safran and D. Lancet,
in 'Bioinformatics for Omics Data: Methods and Protocols', B. Mayer ed.,Methods in Molecular Biology, Humana Press NY.
http://www.springer.com/

Statistical Analysis Principles for Omics Data
D. Dunkler, F. Sánchez-Cabo and G. Heinze,
in 'Bioinformatics for Omics Data: Methods and Protocols', B. Mayer ed.,Methods in Molecular Biology, Humana Press NY
http://www.springer.com/

Omics-bioinformatics in the Context of Clinical Data
G. Mayer, G. Heinze, H. Mischak, M.E. Hellemons, H.J. Lambers Heerspink, S.J.L. Bakker, D. de Zeeuw, M. Haiduk, P. Rossig and R. Oberbauer,
in 'Bioinformatics for Omics Data: Methods and Protocols', B. Mayer ed.,Methods in Molecular Biology, Humana Press NY.
http://www.springer.com/

Linking transcriptomics and proteomics data on the level of protein interaction networks
Paul Perco, Irmgard Mühlberger, Gert Mayer, Rainer Oberbauer, Arno Lukas, and Bernd Mayer
Electrophoresis; Volume 31 Issue 11, Pages 1280-1789;2010
http://onlinelibrary.wiley.com/

Data Annotation and Relations Modeling for Integrated Omics in Clinical Research
A. Lukas and B. Mayer,
IIOABJ, 2010; Vol.1 (2): 15-23
http://www.iioabj2010.webs.com/

Scientific Presentations

American Society of Nephrology (ASN) Renal Week 2011
November 9-13, 2011, Philadelphia, PA, USA

The following SysKid members attended this year’s ASN Renal Week 2011:

Stephan Bakker, Dick de Zeeuw, Danilo Fliser, Hiddo Heerspink, Merel Hellemons, Maria Lajer, Patrick Mark, Gert Mayer, Rainer Oberbauer, Markus Pirklbauer, Laszlo Rosivall, Peter Rossing, Michael Rudnicki, Andrzej Wiecek, Julia Wilflingseder, Carmine Zoccali, Carlamaria Zoja

Presentation titles of contributions at the ASN are listed below:

Merel Hellemons

- Inital Angiotensin Receptor Blockade induced Decrease in Albuminuria is Associated with Long Term Renal Outcome in Type 2 Diabetic Patients with Microalbuminuria; a Post-hoc Analysis of the IRMA-2 trial. [Poster TH-PO24]

- Growth-differentiation Factor 15 and High-sensitivity Troponin-T Predict Progression of Albuminuria in Diabetes and Hypertension; results of a nested case-control study. [Poster TH-PO50]

Danilo Fliser

- Chairman of the session Dialysis: Anemia, Malnutrition, and Metabolism

Merel Hellemons

- Growth-differentiation Factor 15 and High-sensitivity Troponin-T Predict Progression of Albuminuria in Diabetes and Hypertension; results of a nested case-control study. [Poster TH-PO50]

Carmine Zoccali

- Phosphate, CKD Progression and ACE-Inhibition: A post-hoc Analysis of the REIN Trial.

- Visit to visit blood pressure variability and cardiovascular risk in CKD patients.

Carlamaria Zoja

- Effects of MCP-1 inhibition by bindarit therapy in a rat model of polycystic kidney disease (PKD). [Poster SA-PO2219]

Peter Rossing

- Aliskiren Added to Losartan Has Beneficial Effects across Different Levels of Albuminuria in Hypertensive Patients with Type 2 Diabetes and Nephropathy: The AVOID Study [TH-PO520]

- FGF23 and Asymptomatic Coronary Artery Disease in Type 2 Diabetic Patients with Elevated Urinary Albumin Excretion Rate [TH-PO512]

- YKL-40 Levels Are Associated with Coronary Calcium Score in Type 2 Diabetic Patients with Albuminuria but without Known Cardiovascular Disease [TH-PO510]

- Spironolactone Diminishes Urinary Albumin Excretion in Type 1 Diabetic Patients with Microalbuminuria: A Randomized Placebo-Controlled Crossover Study [TH-PO548]

- Is Microalbuminuria Still the Primary Marker of Early Diabetic Nephropathy?

Peter Rossing, Maria Lajer

- Blood Pressure Measurement in Diabetes – New Techniques and Validity of Current Modalities in Hypertension Diagnostics [PUB391]

- Evaluation of Bone Mineral Density in Long-Standing Type 1 Diabetic Patients with or without Diabetic Nephropathy [SA-PO2280]

Peter Rossing, Merel Hellemons, Stephan Bakker, Dick de Zeeuw, Hiddo Heerspink

- Albuminuria Response to Angiotensin Receptor Blockade Is a Determinant of Renal Protection in Patients with Type 2 Diabetes and Microalbuminuria in the IRMA-2 Trial [TH-PO245]

Peter Rossing, Stephan Bakker

- Urinary Sulphate Excretion Is a Predictor for Progression of Diabetic Nephropathy [TH-PO498]

Julia Wilflingseder

- Renal allograft rejection and delayed graft function regulated by miRNAs

Markus Pirklbauer

- Oncostatin M is a Novel Inhibitor fo TGF-beta1-induced CTGF Expression in Human Proximal Tubular Cells.

SysKid first annual meeting
hosted by the Medical University of Innsbruck will include a public session on Friday, the 28th of January 2011, from 15:00 – 18:00. Topics covered will range from Omics, models and Systems Biology in clinical research to specific topics in chronic kidney disease.
January 28,2011, Innsbruck, Austria

Time-to-event analyses with time-dependent effects'
Daniela Dunkler
Biometric Seminar of the German Cancer Research Center (DKFZ)
Dec 13, 2010, Heidelberg, Germany

poster sessions at the ASN Renal Week
Nov 16-21, 2010-11-03, Denver, CO, US
including:

- Poster: "Discovery of Novel Biomarkers for Diagnostics of Diabetic Nephropathy"
Ulrika Lundin, Klaus Weinberger

- Poster: "Lack of the lectin-like domain of thrombomodulin worsens Shigatoxin (Stx)-induced HUS in mice."
Carlamaria Zoja

- Poster: "Targeting Keap1-Nrf2 pathway ameliorates renal inflammation and fibrosis in mice with protein-overload proteinuria."
Carlamaria Zoja

Metabolomic Profiling of Chronic Allograft Nephropathy resulting from Immunosuppressant Therapies in Post Renal Transplantation Patients
HUPO 10th Annual World Congress
Michael Ryan, Tara McMorrow
September 3-7, 2011, Geneva, Switzerland

Oncostatin M is a novel inhibitor of TGF-beta1-induced matricellular protein expression in human proximal tubular cells.
Markus Pirklbauer
3. Kongress für Nephrologie der Deutschen Gesellschaft für Nephrologie
September 10-13, 2011 Berlin, Germany

mTOR-inhibition modifies growth factor induced fibroblast, osteoblast and vascular smooth muscle cell differentiation of human mesenchymal stem cells.
3. Kongress für Nephrologie der Deutschen Gesellschaft für Nephrologie
Theres Schaub, Björn Hegner, Duska Dragun
September 10-13, 2011 Berlin, Germany

A systematic analysis of uremic retention solute’s effects on mesenchymal stem cell biology.
Björn Hegner, Joachim Jankowski, Duska Dragun
3. Kongress für Nephrologie der Deutschen Gesellschaft für Nephrologie
September 10-13, 2011 Berlin, Germany

Pre-transplant sensitization against Angiotensin II type 1 receptor (AT1R-antibody) is a novel independent risk factor of antibody-mediated rejection.
3. Kongress für Nephrologie der Deutschen Gesellschaft für Nephrologie
Björn Hegner, Duska Dragun
September 10-13, 2011 Berlin, Germany

An empirical comparison of fixed and random effects models in survival.
Daniela Dunkler
Annual Conference of the International Society for Clinical Biostatistics (ISCB)
August 21-25, 2011 Ottawa, Canada

Estimation of Nonlinear Interactions in Cox Regression.
Maria Kohl
Annual Conference of the International Society for Clinical Biostatistics (ISCB)
August 21-25, 2011 Ottawa, Canada

Oncostatin M is a novel inhibitor of basal and TGF-beta1 induced matricellular protein expression in human proximal tubular cells
Markus Pirklbauer
World Congress of Nephrology (WCN)
April 8-12, 2011 Vancouver, Canada

Initial Angiotensin Receptor Blockade induced decrease in albuminuria predicts long term renal outcome in type 2 diabetic patients with microalbuminuria; a post-hoc analysis of the IRMA-2 trial
Hiddo Lambers Heerspink
World Congress of Nephrology (WCN)br />April 8-12, 2011 Vancouver, Canada

miRNA regulation of rejection and delayed graft function in post-transplant kidney donor biopsies
Julia Wilflingseder
World Congress of Nephrology (WCN)
April 8-12, 2011 Vancouver, Canada

Haemoglobin variability affects survival or renal allograft
Julia Wilflingseder
World Congress of Nephrology (WCN)
April 8-12, 2011 Vancouver, Canada

Sirolimus induced phosphaturia is not caused by NaPi2a and NaPi2c dysregulation
Maria Haller
World Congress of Nephrology (WCN)
April 8-12, 2011 Vancouver, Canada

Validity of biomarkers for the prediction of albuminuria and progression of diabetic nephropathy in type 2 diabetes: a systematic review
Hannes Neuwirt
World Congress of Nephrology (WCN)
April 8-12, 2011 Vancouver, Canada

Versican as a novel biomarker for progression of chronic kidney disease
Hannes Neuwirt
World Congress of Nephrology (WCN)
April 8-12, 2011 Vancouver, Canada

Growth factor microenvironment is decisive for mesenchymal stem cell regenerative capacity and determines vascular smooth muscle cell or fibroblastic differentiation
Björn Hegner, Duska Dragun
American Transplant Congress (ATC)
April 30-May 4, 2011 Philadelphia, US

Better appreciation of true biological miRNA expression differences using an improved version of the global mean normalization strategy
Jo Vandesompele – Biogazelle NV
Advances in qPCR / RNAi & miRNA World Congress
Boston 26-27 April 2011

Time-to-event analyses with time-dependent effects'
Daniela Dunkler
Biometric Seminar of the German Cancer Research Center (DKFZ)
Dec 13, 2010, Heidelberg, Germany

ASN Renal Week
Nov 16-21, 2010-11-03, Denver, CO, US

- Poster: "Discovery of Novel Biomarkers for Diagnostics of Diabetic Nephropathy"
Ulrika Lundin, Klaus Weinberger

- Poster: "Lack of the lectin-like domain of thrombomodulin worsens Shigatoxin (Stx)-induced HUS in mice."
Carlamaria Zoja

- Poster: "Targeting Keap1-Nrf2 pathway ameliorates renal inflammation and fibrosis in mice with protein-overload proteinuria."
Carlamaria Zoja

Estimation of Nonlinear Interactions in Cox Regression
Maria Kohl
International 15th Young Statisticians Meeting
Oct 30, 2010, Vorau, Austria
http://www.stat.tugraz.at/ysm15/

Biogazelle Booth at qPCR EUROPE
Biogazelle
qPCR EUROPE
Sept 14 - 15, 2010, Dublin, Ireland
http://www.selectbiosciences.com/conferences/AqPCR2010/

Course - qPCR experiment design and data analysis-analysis
Biogazelle
Sept 17 - 18 2010, Dublin, Ireland
Nov 8 - 9 2010, Ghent, Belgium

Time to Event analyses with Time-Dependent Effects
Daniela Dunkler
1st Joint DIA/EMA Workshop on Statistical Methodology in Clinical R&D
Sept 27 - 29 2010, Vienna, Austria
download programme

Data integration and relations modeling for integrating Omics in clinical research
Paul Perco
4th Central and Eastern European Proteomics Conference meets International Metabolomics Austria
Aug 29 – Sept 03 2010, Vienna, Austria
http://www.cta.tuwien.ac.at/ceepc-ima/

Nonlinear time-dependent effects in Cox regression with moderate sample sizes
Daniela Dunkler, Maria Kohl, Meinhard Ploner, Georg Heinze
31st Annual Conference of the International Society for Clinical Biostatistics (ISCB)
Aug 29 – Sep 2, 2010, Montpellier, France

Panel discussion “Genomics in Medicine”
Doron Lancet
14th International Conference on Research in Computational Molecular Biology (RECOMB 2010),
Aug 12-15, 2010, Lisbon, Portugal

Systems biology analysis of chronic kidney disease
Paul Perco
Meeting: EuroKUP meeting
March 20 2010, Rotterdam, The Netherlands

several presentations were held at the:

XLVII ERA-EDTA Congress
II DGfN Congress
June 25 - 28 2010 Munich, Germany
http://www.eraedta2010.org/sprogram.htm

- GWAS and renal outcomes
Rainer Oberbauer, Linz, Austria

- Transcriptional profiling in nephrology
Gert Mayer, Innsbruck, Austria

- Proteome analysis in the assessment of renal disease
Harald Mischak, Hannover, Germany

- Integration of large scale data sets in renal disease: genetics-genomics-metabolomics
Matthias Kretzler, Ann Arbor, USA

- Approaches for linking the Omics levels
Bernd Mayer, Vienna, Austria

- Standard versus intensified dialysis in AKI in intensive care units
Danilo Fliser, Homburg/Saar, Germany

- The complementary use of Registry data for research into rare diseases
Vianda Stel,ERA-EDTA Registry, Amsterdam, The Netherlands

- Cardiovascular risk biomarkers
Biomarkers: when is it justified to incorporate a new biomarker into clinical practice?
Carmine Zoccali, Reggio Calabria, Italy

- Protein bound uremic toxins
Joachim Jankowski, Berlin, Germany

- The bone (adipocyte) vascular axis
Beyond Ca/P/PTH: clinical evidence of a link between the adipose tissue and bone disease in ESRD
Andrzej Wiecek, Katowice, Poland

- Haemodialysis
Biocompatibility and genomics in dialysis
Rainer Oberbauer, Linz, Austria

- European Cardiovascular and Renal Medicine (EURECAM)
EURECAM mission and results of surveys
Carmine Zoccali, Reggio Calabria, Italy

- Potential and caveats on the use of Clinical Trials data-bases for secondary analyses in Cardiovascular and Renal Medicine
Johannes Mann, Munich, Germany

- ERA-EDTA Nephroquest Working Group
NephroQUEST - different tools to improve the quality of RRT care
K. J. Jager, Amsterdam, The Netherlands

- Immune mechanisms in autoimmune nephritis
Novel roles of chemokines
Carla Zoja, Bergamo, Italy

- Progression of renal damage
Capillary rarefication, angiogenesis and VEGF in the progression of renal disease
Gert Mayer, Innsbruck, Austria

- Growth factors in renal regeneration
Josep M. Cruzado, Barcelona, Spain

- Prevention of cardiovascular risk in renal patients
Effect of blood pressure lowering on cardiovascular morbidity and mortality in people with chronic kidney disease
Hiddo J. Lambers Heerspink, Groningen, The Netherlands

- Practices in renal transplantation
Cardiovascular screening of potential transplant recipients
Alan G. Jardine, Glasgow, UK

SME success story in FP7, SYSKID
Bernd Mayer
Meeting: FP7 Health - Open Information Day & Brokerage event
June 8 2010, Brussels, Belgium
Webcast available here

Project presentation SysKid
Joachim Jankwski
Berlin-Brandenburg forscht für Europa
May 6 2010, Berlin, Germany

top

Navigation